TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage

Trial Profile

TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TIMES
  • Most Recent Events

    • 09 Jun 2017 Planned End Date changed from 1 Oct 2019 to 1 Feb 2019.
    • 09 Jun 2017 Status changed from recruiting to discontinued due to safety results.
    • 20 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top